Importantly, the expression of GLUT-1, GLUT-3, and HK2 is reduced in melanoma specimen from patients treated by pharmacological BRAFV600E inhibitors (BRAFi) and is reexpressed after relapse suggesting a critical role of glycolysis in melanoma progression. Here, SLC2A1 is linked to melanoma.